INTRODUCTION - For All Patients from Any Country

Thank you for taking part in this online survey of patients. This survey will be used as part of Lymphoma Canada's and CLL Patient Advocacy Group's submission to the pan-Canadian Oncology Drug Review (www.pCODR.ca). The pan-Canadian Oncology Drug Review (pCODR) assesses cancer drugs and makes recommendations to the provinces and territories to guide their drug funding decisions.

The purpose of this survey is to help develop a complete and thorough submission to help governments understand the value of new cancer drugs to patients and their caregivers. The drug therapies that will soon be reviewed by pCODR are:
  1. Venetoclax + obinutuzumab for first-line treatment of CLL/SLL
  2. Acalabrutinib + obinutuzumab for first-line treatment of CLL/SLL
  3. Acalabrutinib monotherapy for first-line treatment of CLL/SLL
  4. Acalabrutinib monotherapy for treatment of relapsed/refractory CLL/SLL 
Your feedback is extremely important and may help improve access to new treatments for CLL/SLL patients in Canada. The greater the response the better our data will be. The survey results may also be shared with other international groups who are submitting patient experience data for drug submissions. We will ensure no identifying information is shared.
 
YOU DO NOT HAVE TO BE A CANADIAN RESIDENT TO RESPOND TO THIS SURVEY; we appreciate input from all patients with CLL & SLL who have experience with Venetoclax + Obinutuzumab OR Acalabrutinib monotherapy OR Acalabrutinib + Obinutuzumab.
 
If you have any questions, concerns, or technical difficulties while completing this survey please contact Elizabeth Lye at: elizabeth@lymphoma.ca or Rebecca at cllpag.canada@gmail.com

Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.

Question Title

* 1. Please indicate which disease you were diagnosed with:

Question Title

* 2. Please select the therapy below which has been used to treat your CLL/SLL.

T